Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.82 |
| ▸ | HTR2C | P28335 | 2/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.82 |
| ▸ | HRH1 | P35367 | 2/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.82 |
| ▸ | DRD3 | P35462 | 2/20 | 0.82 |
| ▸ | HTR2B | P41595 | 2/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | ACHE | P22303 | 1/20 | 0.82 |
| ▸ | HRH2 | P25021 | 1/20 | 0.82 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492883 | 1.00 | SLC6A4 (0.82) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Hydrochloric Acid SCHEMBL2806605 | 0.99 | SLC6A4 (0.81) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL145621 | 0.94 | SLC6A4 (0.88) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2810625 | 0.93 | SLC6A4 (0.72) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Hydrochloric Acid SCHEMBL2805965 | 0.92 | SLC6A4 (0.70) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| (R)-Citalopram SCHEMBL13235283 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL141607 | 0.90 | SLC6A4 (0.81) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL34948 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL946 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL3858802 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242159-B2 | 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-08-14 | — | — | US | claimed |
| US-20100240725-A1 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2010-09-23 | — | — | US | claimed |
| EP-2215070-A2 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | Dong-A Pharmaceutical Co., Ltd. (KR) | 2010-08-11 | — | — | EP | claimed |
| WO-2009057974-A2 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2009-05-07 | — | — | WO | claimed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-8242159-B2 | 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-08-14 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20100240725-A1 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | SLC6A4 178/4885SLC6A2 44/4885HTR2C 2279/4885 |
| US-20100240725-A1 | NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION | SLC18A2, SLC18A1, SLC6A4 | SLC6A4 3/4885SLC6A2 7/4885HTR2C 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.